title: Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.
abstract: An overview is given of serum and urine prostate cancer markers that are currently under investigation and subsequently the P-Mark project is introduced. There are many markers showing promise to overcome the limitations of prostate specific antigen (PSA). Eventually, these markers should be able to increase the specificity in diagnosis, differentiate between harmless and aggressive disease and identify progression towards androgen independence at an early stage. In the P-Mark project, several recently developed, promising markers will be evaluated using clinically well-defined biorepositories. Following successful evaluation, these markers will be validated on a sample set derived from two large, European, prostate cancer studies and used for the identification of special risk groups in the general population. In addition, novel markers will be identified in the same biorepositories by different mass spectrometry techniques.
authors.affiliation: Department of Urology, Erasmus MC, CA Rotterdam, The Netherlands.
authors.forename: M P M Q
authors.initials: MP
authors.lastname: van Gils
authors.forename: U H
authors.initials: UH
authors.lastname: Stenman
authors.forename: J A
authors.initials: JA
authors.lastname: Schalken
authors.forename: F H
authors.initials: FH
authors.lastname: Schröder
authors.forename: T M
authors.initials: TM
authors.lastname: Luider
authors.forename: H
authors.initials: H
authors.lastname: Lilja
authors.forename: A
authors.initials: A
authors.lastname: Bjartell
authors.forename: F C
authors.initials: FC
authors.lastname: Hamdy
authors.forename: K S I
authors.initials: KS
authors.lastname: Pettersson
authors.forename: R
authors.initials: R
authors.lastname: Bischoff
authors.forename: H
authors.initials: H
authors.lastname: Takalo
authors.forename: O
authors.initials: O
authors.lastname: Nilsson
authors.forename: P F A
authors.initials: PF
authors.lastname: Mulders
authors.forename: C H
authors.initials: CH
authors.lastname: Bangma
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D055418:Bone Morphogenetic Protein 6; D019485:Bone Morphogenetic Proteins / Q000097:blood*; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000145:classification; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality* / Q000652:urine; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D020840:Tissue Kallikreins / Q000097:blood*
chemical_list: C525816:BMP6 protein, human; D014408:Biomarkers, Tumor; D055418:Bone Morphogenetic Protein 6; D019485:Bone Morphogenetic Proteins; D020840:Tissue Kallikreins; D017430:Prostate-Specific Antigen